Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

XLO vs STLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XLO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 8–1 Matrix Metrics)

XLO Overall Winner 6-Pillar Tally: XLO 4 – 0 STLN (2 Tie) Matrix Metrics: XLO 8 – 1 STLN

As of Nov 20, 2026, Xilio Therapeutics, Inc. (XLO) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XLO carries a Unified Composite Score of 45.8/100 (HOLD) at $7.56 (N/M Forward P/E, -74.9% operating margin), whereas STLN carries 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. XLO 45.8/100 HOLD), XLO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-74.9% vs. N/A operating margin) and revenue trajectory (-47.6% vs. N/A YoY).
  • Technical & Structure Timing Caution: XLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9); meanwhile STLN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XLO vs STLN
XLO NASDAQ Head-to-Head Winner
Xilio Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$7.56
+0.67% 1D
Market Cap $53.1M
TTM Revenue $55M
Forward P/E N/M
Beta / 30D Vol 0.74β · 63% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $8.09 · SMA50: $8.56
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 175% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 26
RSI-14: 26.4 · SMA20: $4.93 · SMA50: $5.93

6-Pillar Scorecard Institutional Category Breakdown (XLO 4 – 0 STLN)

Columns: Metric · XLO · STLN
1. Valuation Multiples XLO
Forward P/E N/M N/M
Trailing P/E 11.6x N/M
PEG Ratio N/M N/M
EV / Revenue 1.0x N/M
2. Growth & Scale XLO
Revenue Growth (YoY) -47.6% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $55M N/A
Market Cap $53.1M N/A
3. Profitability & Quality XLO
Gross Margin 79.5% N/A
Operating Margin -74.9% N/A
Net Profit Margin -20.9% N/A
Return on Equity (ROE) -38.2% N/A
4. Balance Sheet & Cash Flow XLO
Cash Generation (TTM) -$40M EBITDA N/A
Cash Flow Margin -72.5% EBITDA Mgn N/A
Net Cash / Leverage $10.36 Book/Sh · -38.2% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XLO (8) vs STLN (1)
Institutional Metric XLO STLN Criterion Row Edge
Market Capitalization
Scale
$53.1M N/A Larger Scale XLO
Trailing P/E Ratio
Valuation
11.6x N/M Lower Multiple XLO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-47.6% N/A Higher Growth XLO
Operating Margin (TTM)
Profitability
-74.9% N/A Higher Margin XLO
Net Profit Margin
Profitability
-20.9% N/A Higher Margin XLO
Return on Equity (ROE)
Capital Efficiency
-38.2% N/A Higher ROE XLO
52-Week Range Position
Momentum
75% ($0–$10) 1% ($3–$7) Stronger Trend XLO
Beta / 30D Volatility
Risk Regime
0.74β · 63% Vol 1.42β · 175% Vol Lower Realized Risk XLO
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite STLN
Trailing 12M Revenue (USD)
Operating Scale
$55M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
79.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$40M EBITDA ($10.36 Book/Sh · -38.2% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XLO +50.73 pp
XLO: -5.85% · STLN: -56.58%
3M Horizon XLO +33.32 pp
XLO: -17.74% · STLN: -51.06%
6M Horizon XLO +25.14 pp
XLO: -16.83% · STLN: -41.97%
1Y Horizon XLO +25.14 pp
XLO: -16.83% · STLN: -41.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XLO vs STLN. Trailing 12-month operating profitability (XLO -74.9% vs STLN N/A) and valuation multiples (XLO N/M vs STLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XLO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$55M
Gross Margin79.5%
Op. Margin-74.9%
ROE / Fwd P/E-38.2% · N/M
STLN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XLO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XLO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XLO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $53.1M market capitalization and -74.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STLN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XLO vs STLN Key Questions & Quantitative Answers

As of Nov 20, 2026, Xilio Therapeutics, Inc. (XLO) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XLO carries a Unified Composite Score of 45.8/100 (HOLD) at $7.56 (N/M Forward P/E, -74.9% operating margin), whereas STLN carries 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. XLO 45.8/100 HOLD), XLO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-74.9% vs. N/A operating margin) and revenue trajectory (-47.6% vs. N/A YoY). Technical & Structure Timing Caution: XLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9); meanwhile STLN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XLO leads the Growth & Scale pillar: XLO posts -47.6% YoY revenue growth and +0.0% YoY earnings growth on $55M TTM revenue (79.5% gross margin, -74.9% operating margin), compared with STLN at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XLO generates $55M in USD-normalized revenue versus N/A for STLN. In operating R&D and SG&A reinvestment, XLO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STLN.

XLO screens cheaper on headline valuation multiples. XLO trades at N/M Forward P/E, 11.6x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-72.5% EBITDA margin), whereas STLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XLO (-38.2% ROE) versus STLN (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, XLO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 63% Vol realized risk). By comparison, STLN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 175% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.